Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis

Hepatology Research

Volumn 47, Issue 12, 2017, Pages 1317-1328

  Okura, Yasushi ^a   Namisaki, Tadashi ^a   Moriya, Kei ^a   Kitade, Mitsuteru ^a   Takeda, Kosuke ^a   Kaji, Kosuke ^a   Noguchi, Ryuichi ^a   Nishimura, Norihisa ^a   Seki, Kenichiro ^a   Kawaratani, Hideto ^a   Takaya, Hiroaki ^a   Sato, Shinya ^a   Sawada, Yasuhiko ^a   Shimozato, Naotaka ^a   Furukawa, Masanori ^a   Nakanishi, Keisuke ^a   Saikawa, Soichiro ^a   Kubo, Takuya ^a   Asada, Kiyoshi ^a   Yoshiji, Hitoshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

hepatic fibrogenesis; hepatocarcinogenesis; losartan; non alcoholic steatohepatitis; sitagliptin

Indexed keywords

AMINO ACID; LOSARTAN; SITAGLIPTIN; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL ACTIVATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; FIBROGENESIS; HEPATIC STELLATE CELL; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; NEOVASCULARIZATION (PATHOLOGY); NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 85012975553     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12860     Document Type: Article

References (42)

1. Bedogni G, Miglioli L, Masutti F et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44–52.
2. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 2008; 48(Suppl 1): S104–S112.
3. Kajiyama H, Kikkawa F, Maeda O et al. Increased expression of dipeptidyl peptidase IV in human mesothelial cells by malignant ascites from ovarian carcinoma patients. Oncology 2002; 63: 158–165.
4. Barreira da Silva R, Laird ME, Yatim N et al. Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat Immunol 2015; 16: 850–858.
5. Yoshiji H, Fukui H. Renin-angiotensin system and progression of chronic liver diseases. J Gastroenterol 2006; 41: 1020–1022.
6. Yoshiji H, Kuriyama S, Yoshii J et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001; 34: 745–750.
7. Yoshiji H, Noguchi R, Namisaki T et al. Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis. J Gastroenterol 2014; 49: 1421–1429.
8. Yoshiji H, Noguchi R, Ikenaka Y et al. Impact of renin-angiotensin system in hepatocellular carcinoma. Curr Cancer Drug Targets 2011; 11: 431–441.
9. Kaji K, Yoshiji H, Ikenaka Y et al. Possible involvement of angiogenesis in chronic liver diseases: interaction among renin-angiotensin-aldosterone system, insulin resistance and oxidative stress. Curr Med Chem 2012; 19: 1889–1898.
10. Kaji K, Yoshiji H, Kitade M et al. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. Am J Physiol Gastrointest Liver Physiol 2011; 300: G1094–G1104.
11. Kaji K, Yoshiji H, Ikenaka Y et al. Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. J Gastroenterol 2014; 49: 481–491.
12. Michel MC, Foster C, Brunner HR et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 2013; 65: 809–848.
13. Remuzzi A, Perico N, Amuchastegui CS et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993; 4: 40–49.
14. Kaji K, Yoshiji H, Kitade M et al. Impact of insulin resistance on the progression of chronic liver diseases. Int J Mol Med 2008; 22: 801–808.
15. Kitade M, Yoshiji H, Kojima H et al. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 2006; 44: 983–991.
16. Namisaki T, Noguchi R, Moriya K et al. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis. J Gastroenterol 2016; 51: 162–172.
17. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–1321.
18. Yoshiji H, Kuriyama S, Yoshii J et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003; 52: 1347–1354.
19. Aihara Y, Yoshiji H, Noguchi R et al. Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model. Hepatol Res 2013; 43: 1241–1250.
20. Yoshiji H, Kuriyama S, Kawata M et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 2001; 7: 1073–1078.
21. Bjornsson E. The clinical aspects of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol 2008; 54: 7–18.
22. Yoshiji H, Noguchi R, Ikenaka Y et al. Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. BMC Res Notes 2009; 2: 70.
23. Buko VU, Lukivskaya OY, Zavodnik LV et al. Antioxidative effect of ursodeoxycholic acid in the liver of rats with oxidative stress caused by γ-irradiation. Ukr Biokhim Zh 2002; 74: 88–92.
24. Alter ML, Ott IM, von Websky K et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res 2012; 36: 119–130.
25. Tang FY, Nguyen N, Meydani M. Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VE-cadherin phosphorylation and inactivation of Akt molecule. Int J Cancer 2003; 106: 871–878.
26. Lee CS, Kim YG, Cho HJ et al. Dipeptidyl peptidase-4 inhibitor increases vascular leakage in retina through VE-cadherin phosphorylation. Sci Rep 2016; 6: 29393.
27. Sun CK, Leu S, Sheu JJ et al. Paradoxical impairment of angiogenesis, endothelial function and circulating number of endothelial progenitor cells in DPP4-deficient rat after critical limb ischemia. Stem Cell Res Ther 2013; 4: 31.
28. Brenner C, Krankel N, Kuhlenthal S et al. Short-term inhibition of DPP-4 enhances endothelial regeneration after acute arterial injury via enhanced recruitment of circulating progenitor cells. Int J Cardiol 2014; 177: 266–275.
29. Anz D, Kruger S, Haubner S et al. The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses. Diabetes Obes Metab 2014; 16: 569–572.
30. Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001; 54: 249–264.
31. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52: 1836–1846.
32. Nomoto K, Tsuneyama K, Takahashi H et al. Cytoplasmic fine granular expression of 8-hydroxydeoxyguanosine reflects early mitochondrial oxidative DNA damage in nonalcoholic fatty liver disease. Appl Immunohistochem Mol Morphol 2008; 16: 71–75.
33. Dizik M, Wainfan E. Differences in activity of N2-guanine tRNA methyltransferase II among several inbred strains of mice. J Natl Cancer Inst 1985; 74: 223–228.
34. Wainfan E, Dizik M, Hluboky M et al. Altered tRNA methylation in rats and mice fed lipotrope-deficient diets. Carcinogenesis 1986; 7: 473–476.
35. Shivapurkar N, Wilson MJ, Hoover KL et al. Hepatic DNA methylation and liver tumor formation in male C3H mice fed methionine- and choline-deficient diets. J Natl Cancer Inst 1986; 77: 213–217.
36. Latendresse JR, Pereira MA. Dissimilar characteristics of N-methyl-N-nitrosourea-initiated foci and tumors promoted by dichloroacetic acid or trichloroacetic acid in the liver of female B6C3F1 mice. Toxicol Pathol 1997; 25: 433–440.
37. Moser GJ, Wolf DC, Goldsworthy TL. Quantitative relationship between transforming growth factor-α and hepatic focal phenotype and progression in female mouse liver. Toxicol Pathol 1997; 25: 275–283.
38. Denda A, Kitayama W, Kishida H et al. Development of hepatocellular adenomas and carcinomas associated with fibrosis in C57BL/6 J male mice given a choline-deficient, L-amino acid-defined diet. Jpn J Cancer Res 2002; 93: 125–132.
39. Femia AP, Raimondi L, Maglieri G et al. Long-term treatment with sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats. Int J Cancer 2013; 133: 2498–2503.
40. Jung YA, Choi YK, Jung GS et al. Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis. Diabetes Res Clin Pract 2014; 105: 47–57.
41. Abdelsalam RM, Safar MM. Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways. J Neurochem 2015; 133: 700–707.
42. Fu Y, Zhang R, Lu D et al. NOX2 is the primary source of angiotensin II-induced superoxide in the macula densa. Am J Physiol Regul Integr Comp Physiol 2010; 298: R707–R712.